B-cell post-transplant lymphoproliferative disorders (PTLDs) are an infrequent complication of allogenic stem cell transplantation, usually associated with Epstein-Barr virus (EBV)-infection. Mostly, the tumor cells are of donor origin and the lymphoproliferations resemble diffuse large B-cell lymphoma, 1 but also T-cell lymphoma, 2 Hodgkin's lymphoma, 3 and even leukemias. 1, 4 Late-onset PTLDs occurring more than 1 year 5 after transplantation do not share the same risk-factors as the more frequent early-onset PTLD, such as HLA mismatch, T-cell depletion, severe graft-versus-host disease (GVHD) and treatment with antithymocyte globulin. 5 Information about the involvement of EBV in the latter subset is scarce. 5, 6 There have been proposals to group these tumors together as EBV-negative PTLDs, considering their predominantly late onset and their more aggressive growth. However, the number of such cases seen after bone marrow transplantation is still very low. 7 Here we report a case with occurrence of B-precursor lymphoblastic lymphoma of donor type after initial AML treated with hematopoietic stem cell transplantation (HSCT).
An 18-year-old female patient presented with symptoms of sepsis and AML (FAB M0) was diagnosed. In a bone marrow biopsy, masses of CD34-positive myeloid blasts were seen. Cytogenetic examinations of 12 GTG stained metaphases from unstimulated cells revealed a complex karyotype of 46, XX, der(7), der(10)?t(10;11)(p11.2;q13), der(11)?(10;11)(p11.2;q13)[10]/46,XX [2] The patient underwent treatment with idarubicin (12 mg/ m ; days 1,3,5 and 7) resulting in complete remission. After 3 months, the second-stage treatment was repeated.
Owing to the delayed response to chemotherapy and the complex karyotype, an allogenic HSCT was performed. The HLA-identical, 23-year-old brother served as donor. Hematopoiesis of the transplant started quickly without observable GvHD. GvHD-prophylaxis used was done with cyclosporin A and methotrexate for a period of 10 months without any signs of GvHD. At 15 months after transplant, the patient noticed a mass of 2 cm size in her right breast. Histology showed a monomorphic blastoid, CD34, CD20, CD45 and terminal deoxynucleotidyltransferase (TdT)-positive infiltrate, and 50% of the tumor cells stained for Ki-67.
The patient is currently being treated with anti-CD20 antibodies and CHOP chemotherapy, resulting after three cycles in partial remission. Up to now the brother has not shown any signs of an hematological disease.
We used a modified version of the Chromogenic in Situ Hybridisation (CiSH) protocol described previously, 8 with a Y-chromosome-specific centromere probe (Appligene-Oncor) in combination with standard immunohistochemistry for cytokeratine (KL-1, Beckman-Coulter, Immunotech). Briefly, a 5 mm-thick tissue slide of the formaline fixed and paraffin embedded tumor was deparaffinized, graded in alcohol and incubated with a KL-1 antibody. For detection, BCIP/NBT/INT was used. an Overnight incubation with a DNA-probe for the Ychromosome followed. The detection of the CISH-signals was performed with tyramide-induced amplification and staining with AEC+.
For verification of the CiSH results, we used the short tandem repeat (STR)-PCR method described previously. 9 The tumor morphologically and immunohistochemically resembled a B-precursor lymphoblastic lymphoma. CiSH showed a single distinct signal in about 75% of the tumor cells representing a Y-chromosome. Remaining mammary ducts and acini, sometimes barely recognizable because of tumor infiltration, could reliably be detected with the pankeratin marker KL-1 and showed no CISH-signals for the Y-chromosomes (Figure 1) .
STR-PCR resulted in a peak pattern that consisted of a combination of donor and recipient-DNA in the tumor. Quantitative analysis showed a nearly four-fold predominance of DNA of donor type, matching roughly the numerical cellular relations (data not shown).
The results of both CiSH and STR-PCR clearly indicated that the extranodal lymphoblastic tumor was not one of the very few adult cases of mixed lineage leukemia with an AML to ALL switch, but a PTLD of donor type with the typical aspects of a B-precursor lymphoblastic lymphoma.
This case clearly differs from typical PTLD described so far. To the best of our knowledge, PTLD presenting as extranodal, tumor-forming B-precursor lymphoblastic lymphoma have not been reported before. Whereas extranodal localization is typical for EBV-positive PTLD, this feature is uncommon for lymphoblastic type of PTLD. In all nine cases of PTLD of ALL-type reported in the literature, 4 the blasts were detected in the peripheral blood or as infiltrations of the bone marrow.
Furthermore, the graft was not HLA-mismatched, there was no episode of GvHD and several highly sensitive tests (EBV-PCR, Anti-EBV IgM as well as staining for EBV (LMP) and EBER in the tumor, data not shown) showed no evidence of an EBV infection.
Considering the rather late occurrence of 15 months after transplantation this case seems to support the view 7 that EBV-negative PTLD form a distinct subgroup, which does not share the same risk factors and tends to have a later onset than EBV-positive PTLD. 
